Cogent Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
COGT$33.54+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $217,461 | $312,012 |
| Short-term marketable securities | 573,673 | 588,753 |
| Prepaid expenses and other current assets | 12,450 | 9,590 |
| Total current assets | 803,584 | 910,355 |
| Operating lease, right-of-use assets | 21,918 | 18,078 |
| Property and equipment, net | 4,311 | 5,457 |
| Restricted cash | 416 | 416 |
| Other assets | 1,913 | 3,301 |
| Total assets | $832,142 | $937,607 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,940 | $9,504 |
| Accrued expenses and other current liabilities | 65,601 | 52,902 |
| Operating lease liabilities | 1,577 | 1,547 |
| Total current liabilities | 73,118 | 63,953 |
| Convertible senior notes, net | 223,744 | 222,895 |
| Operating lease liabilities, net of current portion | 18,899 | 14,355 |
| Other liabilities | 123 | 33 |
| Total liabilities | 315,884 | 301,236 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 8,979,420 shares authorized; no shares issued or outstanding | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 39,414 and 67,414 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 29,190 | 53,830 |
| Series B non-voting convertible preferred stock, $0.001 par value; 20,580 shares authorized; 4,516 shares issued and outstanding at September 30, 2026 and December 31, 2025 | 35,563 | 35,563 |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 173,983,719 and 160,980,024 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 174 | 161 |
| Additional paid-in capital | 1,945,651 | 1,734,882 |
| Accumulated other comprehensive (loss) income | (717) | 355 |
| Accumulated deficit | (1,493,603) | (1,188,420) |
| Total stockholders’ equity | 516,258 | 636,371 |
| Total liabilities and stockholders’ equity | $832,142 | $937,607 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.